Osteoprotegerin and bone mineral density in hemodialysis patients

Osteoporosis International

Volumn 17, Issue 6, 2006, Pages 841-846

  Nakashima, A ^a   Yorioka, N ^a   Doi, S ^a   Takasugi, N ^b   Shigemoto, K ^c   Kohno, N ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Hakuai Hospital   (Japan)

^c Harada Hospital   (Japan)

Author keywords

Bone metabolism markers; Bone mineral density; Hemodialysis; Osteoprotegerin; Renal osteodystrophy

Indexed keywords

BIOLOGICAL MARKER; CALCITRIOL; OSTEOPROTEGERIN; PARATHYROID HORMONE;

ARTICLE; BONE ATROPHY; BONE DENSITY; BONE METABOLISM; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MULTIPLE REGRESSION; NEPHROSCLEROSIS; OSTEOLYSIS; PRIORITY JOURNAL; TREATMENT DURATION;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; DENSITOMETRY, X-RAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; REGRESSION ANALYSIS; RENAL DIALYSIS;

EID: 33646886129     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-0047-0     Document Type: Article

References (25)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, RenshawGegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
2. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
3. Lacey DL, Timms E, Tan HL, Kelly MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
4. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268
5. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Comibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610-615
6. Khosla S, Arrighi HM, Melton LJ III, Atkinson EJ, O'Fallon WM, Dunstan C, Riggs BL (2002) Correlates of osteoprotegerin levels in women and men. Osteoporosis Int 13:394-399
7. Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K, Fukagawa M (2002) Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 39:525-532
8. Misra M, Soyka LA, Miller KK, Herzog DB, Grinspoon S, De Chen D, Neubauer G, Klibanski A (2003) Serum osteoprotegerin in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 88:3816-3822
9. Sato T, Tominaga Y, Iwasaki Y, Kazama JJ, Shigematsu T, Inagaki H, Watanabe I, Katayama A, Haba T, Uchida K, Fukagawa M (2001) Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis 38(Suppl):S175-177
10. Kazama JJ, Omori K, Takahashi N, Ito Y, Maruyama H, Narita I, Gejyo F Iwasaki Y, Fukagawa M (2005) Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 64:64-68
11. Turk S, Akbulut M, Yildiz A, Gurbilek M, Gonen S, Tombul Z, Yeksan M (2002) Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron 90:188-194
12. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl):S1-S202
13. Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4:643-646
14. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Domenig C, Zsontsich T, Klaus K, Delling G, Oberbauer R (2002) Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decrease bone mineralization in hemodialysis patients. Am J Kidney Dis 39:580-586
15. Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L, Manni M, Morosetti M, Moscaritolo E, Sardella D, Bonucci E (2002) Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 17:233-238
16. Lee SK, Lorenzo JA (1999) Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140:3552-3561
17. Onyia JE, Miles RR, Yang X, Halladay DL, Hale J, Glasebrook A, McClure D, Seno G, Churgay L, Chandrasekhar S, Martin TJ (2000) In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15:863-871
18. Browner WS, Lui LY, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631-637
19. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88:1024-1028
20. Fu M, Zhang J, Lin Y, Zhu X, Willson TM, Chen YE (2002) Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. Biochem Biophys Res Commun 14:597-601
21. Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, Komeda K, Miki H, Kubota N, Terauchi Y, Tsuchida A, Tsuboyama-Kasaoka N, Yamauchi N, Ide T, Hori W, Kato S, Fukayama M, Akanuma Y, Ezaki O, Itai A, Nagai R, Kimura S, Tobe K, Kagechika H, Shudo K, Kadowaki T (2001) Inhibition of RXR and PPAR gamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108:1001-1013
22. Olesen P, Ledet T, Rasmussen LM (2005) Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 48:561-568
23. Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F (2000) Tumor necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. J Intern Med 248:67-76
24. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H (1998) Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 18:1199-1202
25. Pei Y, Hercz G, Greenwood C, Manuel A, Saipoo C, Goodman WG, Segre GV, Fenton S, Sherrard DJ (1993) Renal osteodystrophy in diabetic patients. Kidney Int 44:159-164